

勝野 雅央 (Masahisa Katsuno)

〔原著〕

1. *Katsuno M, Adachi H, Minamiyama M, Waza M, Doi H, Kondo N, Mizoguchi H, Nitta A, Yamada K, Banno H, Suzuki K, Tanaka F, *Sobue G. (2010) Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. *J Neurosci*. 30: 5702-5712.
2. Mo K, Razak Z, Rao P, Yu Z, Adachi H, Katsuno M, Sobue G, Lieberman AP, Westwood JT, *Monks DA. (2010) Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy. *PLoS One* 5: e12922.
3. Iida A, Takahashi A, Kubo M, Saito S, Hosono N, Ohnishi Y, Kiyotani K, Mushiroda T, Nakajima M, Ozaki K, Tanaka T, Tsunoda T, Oshima S, Sano M, Kamei T, Tokuda T, Aoki M, Hasegawa K, Mizoguchi K, Morita M, Takahashi Y, Katsuno M, Atsuta N, Watanabe H, Tanaka F, Kaji R, Nakano I, Kamatani N, Tsuji S, Sobue G, Nakamura Y. *Ikegawa S. (2011) A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. *Hum Mol Genet*. 20: 3684-3692.
4. Yu Z, Wang AM, Adachi H, Katsuno M, Sobue G, Yue Z, Robins DM, *Lieberman AP. (2011) Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. *PLoS Genet* 7: e1002321.
5. Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z, Doi H, Matsumoto S, Kondo N, Iida M, Tohnai G, Tanaka F, Muramatsu S, Sobue G. (2012) Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. *Nat Med*. 18: 1136-1141.
6. Rinaldi C, Bott LC, Chen KL, Harmison GG, Katsuno M, Sobue G, Pennuto M, *Fischbeck KH. (2012) Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. *Mol Med*. 18: 1261-1218.
7. Minamiyama M, *Katsuno M, Adachi H, Doi H, Kondo N, Iida M, Ishigaki S, Fujioka Y, Matsumoto S, Miyazaki Y, Tanaka F, Kurihara H, *Sobue G. (2012) Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. *Nat Med*. 18: 1531-1538.
8. Sahashi K, Hua Y, Ling KK, Hung G, Rigo F, Horev G, Katsuno M, Sobue G, Ko CP, Bennett CF, *Krainer AR. (2012) TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals. *Genes Dev*. 26: 1874-84.
9. Katsumata R, Ishigaki S, Katsuno M, Kawai K, Sone J, Huang Z, Adachi H, Tanaka F, Urano F, *Sobue G. (2012) c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. *PLoS One* 7: e46185.
10. Fujita K, Nakamura Y, Oka T, Ito H, Tamura T, Tagawa K, Sasabe T, Katsuta A, Motoki K, Shiwaku H, Sone M, Yoshida C, Katsuno M, Eishi Y, Murata M, Taylor JP, Wanker EE, Kono K, Tashiro S, Sobue G, La Spada AR, *Okazawa H. (2013) A functional deficiency of TERA/VCP/p97 contributes to impaired DNA repair in multiple polyglutamine diseases. *Nat Commun*. 4: 1816.

11. Ikenaka K, Kawai K, Katsuno M, Huang Z, Jiang YM, Iguchi Y, Kobayashi K, Kimata T, Waza M, Tanaka F, Mori I, *Sobue G. (2013) dnc-1/dynactin 1 knockdown disrupts transport of autophagosomes and induces motor neuron degeneration. *PLoS One* 8: e54511.
12. Suga N, *Katsuno M, Koike H, Banno H, Suzuki K, Hashizume A, Mano T, Iijima M, Kawagashira Y, Hirayama M, Nakamura T, Watanabe H, Tanaka F, *Sobue G. (2014) Schwann cell involvement in the peripheral neuropathy of spinocerebellar ataxia type 3. *Neuropathol Appl Neurobiol.* 40: 628-639.
13. Qiang Q, *Adachi H, Huang Z, Jiang YM, Katsuno M, Minamiyama M, Doi H, Matsumoto S, Kondo N, Miyazaki Y, Iida M, Tohnai G, *Sobue G. (2013) Genistein, a natural product derived from soybeans, ameliorates polyglutamine-mediated motor neuron disease. *J Neurochem.* 126: 122-130.
14. Iguchi Y, Katsuno M, Niwa JI, Takagi S, Ishigaki S, Ikenaka K, Kawai K, Watanabe H, Yamanaka K, Takahashi R, Misawa H, Sasaki S, Tanaka F, *Sobue G. (2013) Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. *Brain* 136: 1371-1382.
15. Doi H, *Adachi H, Katsuno M, Minamiyama M, Matsumoto S, Kondo N, Miyazaki Y, Iida M, Tohnai G, Qiang Q, Tanaka F, Yanagawa T, Warabi E, Ishii T, *Sobue G. (2013) p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model. *J Neurosci.* 33: 7710-7727.
16. Takagi S, Iguchi Y, *Katsuno M, Ishigaki S, Ikenaka K, Fujioka Y, Honda D, Niwa J, Tanaka F, Watanabe H, Adachi H, *Sobue G. (2013) RNP2 of RNA recognition motif 1 plays a central role in the aberrant modification of TDP-43. *PLoS One* 8: e66966.
17. Fujioka Y, *Ishigaki S, Masuda A, Iguchi Y, Udagawa T, Watanabe H, Katsuno M, Ohno K, *Sobue G. (2013) FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD. *Sci Rep.* 3: 2388.
18. Honda D, Ishigaki S, Iguchi Y, Fujioka Y, Udagawa T, Masuda A, Ohno K, Katsuno M, *Sobue G. (2013) The ALS/FTLD-related RNA-binding proteins TDP-43 and FUS have common downstream RNA targets in cortical neurons. *FEBS Open Bio.* 4: 1-10.
19. Araki A, *Katsuno M, Suzuki K, Banno H, Suga N, Hashizume A, Mano T, Hijikata Y, Nakatsuji H, Watanabe H, Yamamoto M, Makiyama T, Ohno S, Fukuyama M, Morimoto S, Horie M, *Sobue G. (2014) Brugada syndrome in spinal and bulbar muscular atrophy. *Neurology* 82, 1813-1821.
20. Tohnai G, *Adachi H, Katsuno M, Doi H, Matsumoto S, Kondo N, Miyazaki Y, Iida M, Nakatsuji H, Qiang Q, Ding Y, Watanabe H, Yamamoto M, Ohtsuka K, *Sobue G (2014) Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy. *Hum Mol Genet.* 23: 3552-3565.
21. Riku Y, Watanabe H, Yoshida M, Tatsumi S, Mimuro M, Iwasaki Y, Katsuno M, Iguchi Y, Masuda M, Senda J, Ishigaki S, Udagawa T, *Sobue G. (2014) Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *JAMA Neurol.* 71: 172-179.

22. Chua JP, Reddy SL, Merry DE, Adachi H, Katsuno M, Sobue G, Robins DM, *Lieberman AP. (2014) Transcriptional activation of TFE3/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. *Hum Mol Genet.* 23: 1376-1386.
23. Riku Y, Watanabe H, Yoshida M, Tatsumi S, Mimuro M, Iwasaki Y, Katsuno M, Iguchi Y, Masuda M, Senda J, Ishigaki S, Udagawa T, *Sobue G. (2014) Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *JAMA Neurol.* 71: 172-179.
24. Renier KJ, Troxell-Smith SM, Johansen JA, Katsuno M, Adachi H, Sobue G, Chua JP, Sun Kim H, Lieberman AP, Breedlove SM, *Jordan CL. (2014) Anti-androgen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy. *Endocrinology.* 155: 2624-2634.
25. Iida M, *Katsuno M, Nakatsuji H, Adachi H, Kondo N, Miyazaki Y, Tohnai G, Ikenaka K, Watanabe H, Yamamoto M, Kishida K, *Sobue G. (2015) Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. *Hum Mol Genet.* 24: 314-329.
26. Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, *Sobue G. (2015) Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. *Amyotroph Lateral Scler Frontotemporal Degener.* In press.
27. Oki K, Halievski K, Vicente L, Xu Y, Zeolla D, Poort J, Katsuno M, Adachi H, Sobue G, Wiseman RW, Breedlove SM, *Jordan CL. (2015) Contractile dysfunction in muscle may underlie androgen-dependent motor dysfunction in SBMA. *J Appl Physiol.* In press.
28. Hashizume A, *Katsuno M, Banno H, Suzuki K, Suga N, Mano T, Araki A, Hijikata Y, Grunseich C, Kokkinis A, Hirakawa A, Watanabe H, Yamamoto M, Fischbeck KH, *Sobue G. (2015) A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. *Neuromuscul Disord.* In press.

〔著書・総説〕

1. *Katsuno M, Banno H, Suzuki K, Adachi H, Tanaka F, *Sobue G. (2010) Clinical features and molecular mechanisms of spinal and bulbar muscular atrophy (SBMA). *Adv Exp Med Biol.* 685: 64-74.
2. *Katsuno M, Adachi H, Banno H, Suzuki K, Tanaka F, *Sobue G. (2011) Transforming growth factor-beta signaling in motor neuron diseases. *Current Mol Med.* 11: 48-56.
3. Katsuno M, Tanaka F, *Sobue G. (2012) Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. *J Neurol Neurosurg Psychiatry* 83: 329-335.
4. Katsuno M, Banno H, Suzuki K, Adachi H, Tanaka F, *Sobue G. (2012) Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy. *Arch Neurol.* 69: 436-440.

5. *Katsuno M, Tanaka F, Adachi H, Banno H, Suzuki K, Watanabe H, *Sobue G. (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). *Prog Neurobiol*. 99: 246-256.
6. Iguchi Y, Katsuno M, Ikenaka K, Ishigaki S, *Sobue G. (2013) Amyotrophic lateral sclerosis: an update on recent genetic insights. *J Neurol*. 260: 2917-2927.
7. *Katsuno M, Watanabe H, Yamamoto M, *Sobue G. (2014) Potential therapeutic targets in polyglutamine-mediated diseases. *Expert Rev Neurother*. 14: 1215-1228. doi:10.1586/14737175.2014.956727.

〔国際学会〕

1. Adachi H, Tohnai G, Katsuno M, Minamiyama M, Doi H, Matsumoto S, Kondo N, Miyazaki Y, Tanaka F, Sobue G. A peony extract alleviates polyglutamine-mediated motor neuron disease. Neuroscience 2010, San Diego, USA, 2010.11.13-17. (ポスター)
2. Iguchi Y, Katsuno M, Takagi S, Sobue G. Oxidative stress induces TDP-43 modification, recapitulating its pathological feature. Neuroscience 2010, San Diego, USA, 2010.11.13-17. (ポスター)
3. Katsuno M, Adachi H, Minamiyama M, Doi H, Kondo N, Matsumoto S, Miyazaki Y, Banno H, Suzuki K, Tanaka F, Sobue G. Disrupted TGF-beta signaling in spinal and bulbar muscular atrophy. 21st International Symposium on ALS/MND. Orlando, USA, 2011.12.11-13. (ポスター)
4. Katsuno M, Adachi H, Kondo N, Minamiyama M, Doi H, Matsumoto S-J, Miyazaki Y, Tanaka F, Sobue G. Cell cycle dysregulation in spinal and bulbar muscular atrophy (SBMA). Gordon conference on CAG triplet repeat disorders, Il Ciocco, Italy, 2011.6.5-10. (ポスター)
5. Kondo N, Katsuno M, Adachi H, Minamiyama M, Doi H, Matsumoto S-J, Miyazaki Y, Tanaka F, Sobue G. Heat shock factor-1(Hsf-1) influences distribution of pathogenic androgen receptor aggregations in model mouse of spinal and bulbar muscular atrophy (SBMA) . Gordon conference on CAG triplet repeat disorders, Il Ciocco, Italy, 2011.6.5-10. (ポスター)
6. Adachi H, Tohnai G, Katsuno M, Minamiyama M, Doi H, Matsumoto S, Kondo N, Miyazaki Y, Tanaka F, Ohtsuka K, Sobue G. A peony extract enhances protein degradation systems and exerts therapeutic effects in the polyglutamine-mediated motor neuron disease. Neuroscience 2011, Washington DC, USA, 2011.11.11-16. (ポスター)
7. Renier KJ, Sobue G, Adachi G, Katsuno M, Breedlove M, Jordan CL. Androgen receptor antagonist can prevent disease in the AR97Q mouse model of SBMA. Neuroscience 2011, Washington DC, USA, 2011.11.11-16. 2011.6.5-10. (ポスター)
8. Adachi H, Doi H, Katsuno M, Matsumoto S, Kondo N, Miyazaki Y, Tohnai G, Iida M, Tanaka F, Sobue G. p62/SQSTM1 removes toxic mutant androgen receptor in spinal bulbar muscular atrophy model mouse. Neuroscience 2012, New Orleans, USA, 2012.10.13-17. (ポスター)
9. Minamiyama M, Katsuno M, Adachi H, Doi H, Kondo N, Iida M, Ishigaki S, Fujioka Y, Matsumoto S, Miyazaki Y, Tanaka F, Kurihara H, Sobue G. Naratriptan ameliorates SBMA pathology by the repression of CGRP1-activated JNK pathway.

- Neuroscience 2012, New Orleans, USA, 2012.10.13-17. (ポスター)
10. Miyazaki Y, Adachi H, Katsuno M, Tanaka F, Muramatsu SI, Sobue G. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Neuroscience 2012, New Orleans, USA, 2012.10.13-17. (ポスター)
 11. Ishigaki S, Fujioka Y, Masuda A, Iguchi Y, Katsuno M, Ohno K, Sobue G. Comparison of Fus-regulating gene expression and alternative splicing profiles among different cell lineages in the central nervous system. Neuroscience 2012, New Orleans, USA, 2012.10.13-17. (ポスター)
 12. Oki K, Adachi H, Katsuno M, Breedlove M, Sobue G, Wiseman RW, Jordan CL. Muscle dysfunction may underlie androgen-dependent motor dysfunction in two mouse models of SBMA. Neuroscience 2012, New Orleans, USA, 2012.10.13-17. (ポスター)
 13. Iguchi Y, Katsuno M, Yamanaka K, Takahashi R, Misawa H, Sasaki S, Tanaka F, Sobue G. Loss of TDP-43 results in age-dependent progressive motor impairment and neuropathological alterations, mimicking motor neuron disease. 23rd International Symposium on ALS/MND. Chicago, USA, 2012.12.5-7. (ポスター)
 14. Katsuno M, Adachi H, Kondo N, Minamiyama M, Doi H, Matsumoto S, Miyazaki Y, Iida M, Nakatsuji H, Tanaka F, Sobue G. Cell cycle dysregulation in motor neurons of spinal and bulbar muscular atrophy (SBMA). 23rd International Symposium on ALS/MND. Chicago, USA, 2012.12.5-7. (ポスター)
 15. Kondo N, Katsuno M, Adachi H, Minamiyama M, Matsumoto S, Nakatsuji H, Miyazaki Y, Iida M, Tohnai G, Sobue G. Heat shock factor-1 (Hsf-1) controls pathological lesion distribution of polyglutamine-induced motor neuron disease. The 24th International Symposium on ALS/MND, Milan, Italy, 2013.12.5-7. (ポスター)
 16. Adachi H, Qiang Q, Hunag Z, Jinag YM, Katsuno M, Kondo N, Miyazaki Y, Iida M, Tohnai G, Nakatsuji H, Sobue G. Genistein, a natural product derived from soybeans, ameliorates polyglutamine-mediated motor neuron disease. Neuroscience 2013, San Diego, USA, 2013.11.9-13. (ポスター)
 17. Hlievski K, Henley CL, Fu M, Katsuno M, Adachi H, Sobue G, Breedlove SM, Jordan CL. Deficits in brain-derived neurotrophic factor may underlie motor dysfunction in spinal bulbar muscular atrophy. Neuroscience 2013, San Diego, USA, 2013.11.9-13. (ポスター)
 18. Ishigaki S, Fujioka Y, Udagawa T, Honda D, Katsuno M, Sobue G. FUS regulates alternative splicing patterns of Mapt by cooperating with PSF/SFPQ: a novel link between FUS and Tau in the pathogenesis of ALS and FTL. Neuroscience 2013, San Diego, USA, 2013.11.9-13. (ポスター)
 19. Fujioka Y, Ishigaki S, Shiromizu T, Udagawa T, Honda D, Yokoi S, Ikenaka K, Katsuno M, Tomonaga T, Sobue G. The involvement of glial cells in FUS-related ALS/FTLD pathophysiology -FUS knock-down glial cells have a neuro-protective effect. Neuroscience 2014, Washington DC, USA. 2014.11.15-19. (ポスター)
 20. Halievski K, Xu Y, Henley CL, Katsuno M, Adachi H, Sobue G, Breedlove S, Jordan CL. Androgen-dependent deficits in muscle-derived BDNF correlate with motor dysfunction in two mouse models of spinal bulbar muscular atrophy. Neuroscience

- 2014, Washington DC, USA. 2014.11.15-19.(ポスター)
21. Xu, Atchison W, Adachi H, Katsuno M, Sobue G, Breedlove S, Jordan CL. SBMA motor dysfunction may be due to failed neuromuscular transmission. Neuroscience 2014, Washington DC, USA. 2014.11.15-19.(ポスター)
 22. Sasaki S, Iguchi Y, Katsuno M, Sobue G. The blood-spinal cord barrier is temporarily impaired in TDP-43 conditional knockout mice. 13th International Congress on Neuromuscular Diseases. Nice, France, 2014.7.5-10.(ポスター)

〔国内学会〕

1. 宮崎 雄, 足立弘明, 勝野雅央, 南山 誠, 蔣 月梅, 土井英樹, 松本 慎二郎, 近藤直英, 飯田 円, 藤内玄規, 田中章景, 村松慎一, 祖父江 元. miR-196aはSBMAにおいて異常AR mRNAの不安定化を促進し表現型を有意に改善させる. 第53回日本神経学会, 東京, 2012.05.22-25.(口演)

〔招待講演・セミナー〕

1. Katsuno M. TGF-beta signal disruption and cell cycle dysregulation in motor neuron diseases. Kick off symposium of Scientific Research on Innovative Area “Foundation of Synapse and Neurocircuit Pathology”, Tokyo, 2010.10.28.
2. 勝野雅央. TGF-βからみた神経変性機序. 第52回日本神経学会学術大会シンポジウム「神経変性をどう考えるか? 病態理解に至る最近の進歩」, 名古屋, 2011.5.19.
3. Katsuno M. Elucidation of neuronal death signaling pathways and development of disease-modifying therapies for Kennedy's disease. Kennedy's Disease Association 2011 Annual Conference and Education Symposium. Bowie, USA, 2011.11.11.
4. 勝野雅央, 坂野晴彦, 鈴木啓介, 橋詰 淳, 足立弘明, 田中章景, 祖父江 元. 神経変性疾患のトランスレーショナルリサーチ. 第109回日本内科学会総会・講演会シンポジウム「わが国のトランスレーショナルリサーチとEBM」, 京都, 2012.4.14.
5. 勝野雅央, 祖父江 元. 球脊髄性筋萎縮症に対する抗アンドロゲン療法. 第53回日本神経学会学術大会シンポジウム「アカデミア発の創薬」, 東京, 2012.5.25.
6. Katsuno M, Adachi H, Minamiyama M, Doi H, Kondo N, Miyazaki Y, Iida M, Tanaka F, Sobue G. Molecular pathogenesis and therapy of polyglutamine-induced motor neuron degeneration. 35th Annual Meeting of the Japan Neuroscience Society, Nagoya, Japan, 2012.9.21.
7. 勝野雅央. 運動ニューロンの老化と変性. 第34回日本生物学的精神医学会シンポジウム『老いを科学する—神経変性の視点から』神戸, 2012.9.29.
8. Katsuno M. Endpoints and biomarkers in clinical trials of neurological disorders. The 3rd International Symposium of Early Stage Clinical Trial, Yokohama, Japan, Feb 2, 2013.
9. 勝野雅央. Dynactin 1の機能低下と運動ニューロン変性. 第54回日本神経学会学術大会シンポジウム「運動ニューロン疾患の遺伝学 update」, 東京, 2013.5.30.
10. Katsuno M. Neurobiological Study of Postmortem Brain from Brain Bank: for the study of spinal disorders. Neuro2013, Kyoto, Japan, 2013.6.22.
11. 勝野雅央. 神経変性疾患における動物モデルから臨床試験への展開, Neuro2013 基礎臨床統合シンポジウム「基礎・臨床連携の推進に向けて:現状の課題と今後の展望」, 京都, 2013.6.21.

12. 勝野雅央. 運動ニューロン疾患に対する治療法開発の現状と展望. 第 4 回神経疾患 HOT TOPICS, 仙台, 2013.7.4.
13. Katsuno M. Translational research on disease-modifying therapy for neurodegenerative disease. Young Scientist Symposium 2013, Tokyo, Japan. 2013.8.31.
14. 勝野雅央. 運動ニューロン疾患に対する分子標的治療法の開発. 第4回神経科学と構造生物学の融合研究会, 岡崎, 2013.11.19-20.
15. 勝野雅央. 神経変性疾患に対する治療法開発の現状と展望. 第 5 回 Neuroprotective Meeting for Researchers (NMYR), 東京, 2013.11.23.
16. Katsuno M, Sobue G. Pathogenesis of selective neurodegeneration in polyglutamine-mediated motor neuron disease. International symposium. New Frontier of Molecular Neuropathology 2014, Tokyo, Japan, 2014.3.16-17.
17. 勝野雅央. 神経変性疾患に対する医師主導治験. 第 11 回医薬品評価フォーラム, 東京, 2014.4.24.
18. Katsuno M. Molecular pathway and therapeutic strategies for motor neuron diseases. The 5th East Asia Neurology Forum (EANF), Kaoshiung, Taiwan, 2014.4.12.

〔研究助成金〕

1. 平成 21－25 年度 日本学術振興会科学研究費補助金 基盤 S 「分子標的を介するポリグルタミン病の根本治療法の開発」 研究代表者 祖父江 元, 分担研究者 勝野雅央
2. 平成 22－26 年度 文部科学省科学研究費補助金 新学術領域 「運動ニューロン疾患におけるニューロサーキット変性の病態と治療法開発」 課題番号:22110005 研究代表者 勝野雅央
3. 平成 22－26 年度 科学技術振興機構戦略的創造研究推進事業 研究領域:精神・神経疾患の分子病態理解に基づく診断・治療へ向けた新技術の創出 「ポリグルタミン病の包括的治療法の開発」 共同研究者 勝野雅央
4. 平成 23－24 年度 Kennedy's Disease Association Research Grant, Elucidation of neuronal death signaling pathways and development of disease-modifying therapies for Kennedy's disease. 研究代表者 勝野雅央 2,000
5. 平成 23－25 年度 日本学術振興会科学研究費補助金 基盤 B 「ポリグルタミン病における細胞周期およびJNKシグナル異常の病態解明と治療法開発」 課題番号:23390230 研究代表者 勝野雅央
6. 平成 24－25 年度 日本学術振興会科学研究費補助金 挑戦的萌芽 「球脊髄性筋萎縮症における活動依存性シナプス病態の解明と治療法の開発」 課題番号:24659428 研究代表者 勝野雅央
7. 平成 25－26 年度 第一三共生命科学研究振興財団研究助成金 研究代表者 勝野雅央
8. 平成 25 年度 日本学術振興会科学研究費補助金 挑戦的萌芽 「球脊髄性筋萎縮症におけるクレアチニン代謝異常の病態解明と探索的臨床試験」 課題番号:26670440 研究代表者 勝野雅央
9. 平成 26－28 年度 日本学術振興会科学研究費補助金 基盤 B 「運動ニューロン疾患における神経・筋システム変性の分子病態解明と治療法開発」 課題番号:26293206 研究代表者 勝野雅央

10. 平成 26－28 年度 日本学術振興会科学研究費補助金 基盤 C 「アンチセンス核酸を用いた運動ニューロン疾患の病態、治療研究」 課題番号:26461268 研究代表者 佐橋健太郎, 分担研究者 勝野雅央

〔特許出願・取得状況〕

特願2012-193347:抗神経変性疾患剤

発明者: 祖父江 元, 勝野雅央

出願人: 国立大学法人名古屋大学

出願日: 2012.9.3.

“Anti-spinal and bulbar muscular atrophy therapy”

発明者: Gen Sobue, Makoto Minamiyama, Masahisa Katsuno

出願人: National Corporation Nagoya University

国際出願日: 2010年12月3日

出願番号: PCT/JP2010/71702

登録日: 2010年11月16日

登録番号: 7833975

〔アウトリーチ〕

該当なし

〔受賞〕

1. 勝野雅央. 2013年度日本神経学会賞. 2014.5.22.
- 2.